All In Biotech

Drug Trial Radar · NCT07947992

Efficacy of Topical Metformin 30% Versus Minoxidil 5% in the Treatment of Alopecia Areata : Comparative Study

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Nov 1, 2027

Study completion Nov 1, 2027

Sponsor

Lead sponsor
Sohag UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate and compare the effectiveness and safety of topical metformin 30% and topical minoxidil 5% in patients with alopecia areata. Alopecia areata is an autoimmune condition that causes non-scarring hair loss, usually presenting as round or oval patches on the scalp. Different topical treatments are used to stimulate hair regrowth, but their effectiveness varies. In this comparative interventional study, eligible patients with alopecia areata will receive either topical metformin 30% or topical minoxidil 5%. Treatment response will be assessed clinically during follow-up using standardized assessment methods, including the Severity of Alopecia Tool (SALT) score, along with clinical and dermoscopic evaluation. The study aims to determine whether topical metformin 30% is an effective treatment option compared with topical minoxidil 5% in patients with alopecia

Conditions

  • Alopecia Areata(AA)

Interventions

  • Metformin 30% Topical LotionDrug

    Topical metformin 30% preparation used for the treatment of alopecia areata.

  • Minoxidil 5 % Topical SprayDrug

    Topical minoxidil 5% preparation used for the treatment of alopecia areata.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in SALT Score from Baseline to Week 12Time frame: Baseline to Week 12 (12 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sohag University Hospital

    Sohag, Sohag Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.